Skip to main
INKT
INKT logo

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics Inc has experienced a remarkable increase of over 400% in share value recently, significantly outperforming the Nasdaq Biotechnology Index, which saw only a 2% rise. The company's innovative platform for iNKT cell therapies allows for scalable and cost-effective manufacturing, offering both native and engineered solutions that retain crucial immunomodulatory properties, thereby enhancing therapeutic efficacy. The forthcoming updates from the Phase 2 gastric trial of agenT-797 are anticipated to further validate the company's strong position in the biopharmaceutical market, providing a solid foundation for future growth.

Bears say

MiNK Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, including potential safety signals from clinical trials and lower-than-expected efficacy from its programs. The company may also encounter increased competition, regulatory challenges, and the need for approximately $55 million in additional financing, projecting a cash runway only into mid-2025. Furthermore, there is a risk of de-listing if the stock price falls below $1, alongside concerns regarding the protection of its intellectual property.

MiNK Therapeutics (INKT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.